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Abstract 
Throughout the last forty years, psychedelic drugs have been illegal in the United States. 
Stigmatized due to the potential for abuse, the use of these drugs has been relegated to simple 
criminal activity and research stagnated for those 40 years. Slowly, research has begun to pick up 
as the restrictions begin to lift incrementally.  However, the current restrictions are intense, 
further limiting the amount of research conducted that can reveal the medical benefits of these 
drugs. Through multiple studies, both open-label and double-blinded to show both feasibility and 
efficacy, as well as the biological impact of the drugs, significant anxiolytic, antidepressant, and 
anti-addictive effects of hallucinogens have been demonstrated. The medical use of these drugs 
could have a lasting effect regarding substance abuse addictions, severe cases of anxiety, and 
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Clinical Uses for Psychedelic Drugs 
         Since the late 1960s, psychedelic drugs have been outlawed in the United States. Prior to 
their ban, psychedelic drugs were thought to have significant medical uses, showing promise in 
treating a broad array of psychological disorders. Because of their proposed medical uses, 
psychedelic drugs were often studied prior to the ban. However, in the late 1960s, a large part of 
the population began to abuse psychedelic drugs and because of this, scientific research 
regarding psychedelics had been slowed. Although some of the barriers to the research and 
medical use of psychedelic drugs have been lifted, they remain heavily stigmatized and 
restricted, limiting the amount and the extensiveness of the research that can be conducted. As 
the restrictions slowly start to lift, research on psychedelics has started to proceed. This research 
has been conducted on lysergic acid diethylamide (LSD), psilocybin, and ayahuasca, a 
hallucinogen originating from the Amazon region of South America. Throughout this paper, 
hallucinogenic and psychedelic drugs will be used interchangeably to refer to drugs that have the 
potential to induce hallucinations or an altered sense of reality. Typically, the hallucinations or 
altered sense of reality are the goals of abuse of these drugs and cause the stigmatization of these 
drugs. However, despite the ban on hallucinogens, the abuse of these drugs has not significantly 
diminished and only serves to majorly limit the research allowed for these drugs. Current 
research indicates that hallucinogens have medical benefits as shown through studies and 
biological processes. The purported uses of psychedelics are as antidepressants, anxiolytics, 
meaning antianxiety, and as anti-addictive drugs. 
Biology 
Outside of clinical trials, hallucinogens demonstrate potential efficacy in the treatment of mood 
disorders. Using functional magnetic resonance imaging (fMRI) to scan the brain, psychedelic 
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drugs exhibited effects correlated to a decrease in mood disorders. Hyperactivity in the medial 
prefrontal cortex of the brain is associated with depression. With administration of psilocybin as 
well as  non-hallucinogenic-based treatments for depression, the medial prefrontal cortex 
displays lessened activity and eventually leading to normalization. fMRIs also revealed that 
amygdala activation resulting from threat related stimuli decreased with the use of psilocybin. 
The amygdala plays a significant role in the creation of emotions and the hyperactivity of this 
section of the brain due to negative stimuli has regularly been associated with negative mood 
states in depressed patients. (Mahaptra, 2017, p. 55) The use of the fMRI to link the activity of 
hallucinogenic drugs with a decrease in brain activity related to depression shows a biological 
basis for clinical use of these drugs. Additionally, since both psychedelic drugs and traditional 
methods of depression treatment created similar responses in the brain, the medical use of these 
drugs is further supported. 
         In addition to the changes in brain activity, other biological factors also contribute to the 
use of hallucinogens as medication. Mahapatra (2017) writes, “Downregulation of 5-HT2A 
receptors is purported to mediate antidepressant and antianxiety effects of antidepressants and 
atypical antipsychotics…Because of the high binding affinity of psilocybin to the 5-HT2A 
receptor, its effects are thought to be mediated.” (p. 54) These receptors are responsible for 
regulation of serotonin, a neurotransmitter. A deficit of this neurotransmitter can often lead to 
depression. Furthermore, the 5-HT2A receptors correspond to additional factors related to 
depression. Idell (2017) explains that expression of 5-HT2A receptors link to neuroinflammation. 
(pg. 50) Heightened levels of neuroinflammation can lead to depression as well and is widely 
regarded as a risk factor for depression. Psilocybin has the potential to regulate the expression of 
5-HT2A receptors and decrease inflammation in the brain. (Idell, 2017, p. 50)  The potential for 
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hallucinogens to reduce depression in patients further supports the proposal for the clinical uses 
of these drugs. 
Antidepressant/Anxiolytic 
The proposed clinical use of psychedelic drugs revolves primarily around their use as 
antidepressants. In a study consisting of 22 patients with depression were treated with LSD 
weekly for 5-6 weeks, eighty percent of patients exhibited improvements in signs of depression 
within  6-18 months. (Rucker et al, 2016) The improvement of eighty percent sits well above the 
threshold for clinical significance and demonstrates the efficacy of the drug. Alternatively, 
Ayahuasca has also been studied as a treatment option for depression. Dos Santos et al. (2016) 
writes “Ayahuasca administration produced statistically significant reductions of up to 82% in 
depressive scores between baseline and 1, 7 and 21 days after drug intake, according to the 
Hamilton Rating Scale for Depression (HAMD), the Montgomery–Åsberg Depression Rating 
Scale (MADRS), and the Anxious–Depression subscale of the Brief Psychiatric Rating Scale 
(BPRS)” (p. 201). In this study, statistically significant numbers relating to decline in depressive 
scores are reached in a short time period after administration of the drug. These numbers also 
appear across a wide range of depression scales. The short term and long term improvement of 
depression with two different psychedelic drugs shows promising signs in the treatment of 
depression. However, these two studies were open-label, meaning these studies show potential or 
feasibility rather than efficacy. 
         Other studies have been conducted in order to test the efficacy of hallucinogens. Ross et 
al. (2016) conducted a study on the efficacy of psilocybin and its role as an antidepressant and 
anxiolytic. This study treated patients with life-threatening cancer who also underwent serious 
anxiety and depression. Unlike the studies mentioned above, this study was double-blinded and 
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tested against Niacin, a placebo. The study concluded that “Psilocybin produced immediate and 
enduring anxiolytic and anti-depressant response rates, as well as significant anti-depressant 
remission rates (measured by the HADS D and BDI).” Using the HAD A and BDI as the scale, 
83% of patients administered psilocybin exhibited an antidepressant response while only 14% of 
those given Niacin exhibited antidepressant responses. Anxiolytic responses occurred in 58% of 
those given psilocybin and only in 14% of those given Niacin (pg. 1175). The chasm between 
antidepressant and anxiolytic effects due to psilocybin and the placebo shows that psilocybin has 
clinical uses. Double-blinded placebo-controlled trials have mostly been done with psilocybin 
although other hallucinogens are used in other studies.  Another study conducted in Switzerland 
in 2014 treated patients with anxiety resulting from life-threatening illness with LSD. This study 
observed similar effects to the double-blinded placebo-controlled psilocybin study. (Cameron, 
2016) The success of LSD in the treatment of these patients shows that the anxiolytic and 
antidepressant effects are present in hallucinogens other than psilocybin. As both of these trials 
were conducted against the placebo in a randomized manner and displayed large increases in 
efficacy of their respective hallucinogens against the placebo, these trials provide ample 
evidence showing that hallucinogens can significantly improve depression and anxiety. 
Anti-addictive 
The most prominent concerns with these drugs are safety and dependence.  The use of 
psychedelic drugs causes great concern regarding potential for dependence.  However , 
Psychedelics “do not induce dependence.” (Rucker et al, 2016, p. 1221) In addition to being non-
addictive, psychedelics are also anti-addictive, meaning they combat dependence on other 
substances. The two substances studied in regards to the anti-addictive effects of psychedelics 
are tobacco and alcohol. 
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Tobacco Dependence 
Hallucinogens have shown potential to combat addictions to tobacco through an open-label 
study. In this study, the average participant smoked 19 cigarettes per day and had smoked for 
approximately three decades. The study measured cigarettes per day prior to and after the 
administration of psilocybin. 6 months after the administration of psilocybin, 80% of the 
participants had not smoked. Additionally, the participants reported less desire to smoke 
throughout the entire duration of the study as well as higher confidence in their ability to 
withstand the temptation to smoke. (Dos Santos, 2016, p. 199-200) Because these smokers had 
smoked for a great length of time, their dependence on nicotine was rather strong. Although the 
study was open-label and undoubtedly affected by the placebo effect, the abstinence of 80% of 
the sample demonstrates massive potential in aiding those who have struggled with nicotine 
addiction. 
Alcohol Dependence 
Equally as tobacco dependence, psychedelic drugs lesson one’s dependence upon alcohol. An 
open-label trial conducted in regards to alcohol dependence administered psilocybin to the 
patients. These patients had been considered alcohol dependent for an average of 15.1 years with 
80% of the sample experiencing withdrawal symptoms prior to the start of the trial. In addition to 
the psilocybin, this trial also included seven sessions of motivational enhancement therapy. 
Throughout the course of the trial, the days in which alcohol was consumed as well as the days 
the patient drank heavily, consuming 4 or more drinks consisting of more than 14 g of alcohol, 
substantially decreased. Throughout the 36 weeks of the trial, the decrease in alcohol dependence 
remained consistent. (Dos Santos, 2016, p. 200)   Compared to the length of time the patients 
depended on alcohol before the study, their decrease in dependence marks a huge improvement.  
7
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Like the Tobacco trial, the alcohol trial was also prone to the placebo effect as it was open-label. 
However, this trial still shows potential relating to the anti-addictive effects of hallucinogens. 
Safety 
The biggest issue concerning the use of hallucinogens to treat mood disorders stems from 
potential adverse effects relating to both physical health and mental health. In clinical trials 
conducted over the safety risks of hallucinogens, most or all patients report no serious adverse 
effects with exceptions regarding ayahuasca and vomiting in 50% of the sample. The patients 
involved in the ayahuasca trial did not regard the vomiting as “causing severe discomfort” (Dos 
Santos et al., 2016; Ross et al, 2016). At first glance the vomiting seems rather serious especially 
considering its appearance in half of the sample. However, out of the three hallucinogens 
commonly discussed in the treatment of mood disorders, only ayahuasca caused the patients to 
vomit. The lack of severe adverse effects by all of the hallucinogens reported means that the use 
of psychedelic drugs in a controlled setting has no known major health consequences. In addition 
to the aforementioned vomiting, other effects have been noted as well. The effects noticed were 
“non-clinically significant elevations in BP [blood pressure] and HR [heart rate] (76%), 
headaches/migraines (28%), and nausea (14%)... transient anxiety (17%) and transient psychotic-
like symptoms (7%: one case of transient paranoid ideation and one case of transient thought 
disorder)” (Ross et al, 2016, p. 1173). Due to the short duration of most of these effects 
combined with a relatively low appearance in the sample, these effects are not significant or 
serious. The one effect that does appear in a large majority of the sample, a rise in blood pressure 
and heart rate, is classified as non-clinically significant. The low incidence in serious and 
clinically significant symptoms in addition to the the short duration of most symptoms 
demonstrates the relative safety of psychedelic drugs. 
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         Additionally, appropriate dosing and drug quality plays a role in the safety of 
hallucinogenic drugs. One study on hallucinogenic drugs conducted by Baumeister et al. (2014) 
stated that adverse effects occurred in a minority of participants, they could all be calmed down 
without medication, and these effects only occurred in patients who had received high doses (p. 
163). The presence of adverse effects in patient who had received high doses indicates a 
correlation between dosage and adverse effects indicating that if lower doses were administered, 
the presence of adverse effects would likely drop. Drug quality is another factor connected to 
severe symptoms. Rucker et al. (2016) writes “The majority of studies of adverse reactions, 
retrospective in nature, have described a constellation of premorbid characteristics in individuals 
seeking treatment for these reactions where drugs of unknown purity were taken in unsupervised 
settings.” (p. 1227) The adverse reactions reported were noticeably low with proper dosages and 
pharmaceutical quality drugs. Additionally, since serious conditions were only noted in those 
who had received high doses and drugs of questionable quality, the use of hallucinogenic drugs 
have limited and non-life threatening side effects when used responsibly.   
Discussion 
Currently, psychedelic drugs are labeled as schedule 1 drugs, meaning these drugs have no 
medical purposes and high potential for abuse. However, as psychedelic drugs have shown to 
exhibit certain clinical uses, such as antidepressant and anxiolytic effects, and have shown 
promise curbing dependence on other substances, to claim these drugs have no medical use 
would be absurd. Additionally, although these drugs could be abused, they are non-addictive. 
Therefore, these drugs have no potential for dependence. Lower classifications do exist for drugs 
that meet the criteria of non-addictive, potential for abuse, and medical purposes. Changing the 
classifications on these drugs would result in lessened restrictions on research of these drugs and 
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their uses and possibly open the door for them to be used to treat mood disorders. Furthermore, 
opiates are currently used in medicine. Opiates have high addiction potential and incur more 
danger and yet morphine is still widely used to anesthetize patients. If drugs that incur 
considerably more danger and have higher addiction potential are commonly used in medicine, 
the use of psychedelic drugs should not be so stigmatized. Since only smaller scale studies have 
been conducted to measure the effects of hallucinogens, more research should be conducted 
before they enter into mainstream clinical use. Lastly, it is important to note that these drugs will 
not be a magical cure for depression. Depression results from both biological and behavioral 
interaction. Without the proper behavioral changes, these drugs will be ineffective. Accordingly, 
due to the multifaceted cause of depression, multiple treatments should be used. Hollister (1969) 
writes “The old adage that the lack of a single effective treatment encourages multiple treatments 
is nowhere more evident.” (p. 171) Since, depression has multiple interrelated causes, multiple 
treatments to combat the different interactions of its root causes becomes all the more necessary. 
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